Diagnosis, treatment, and survival from kidney cancer: real‐world National Health Service England data between 2013 and 2019

Author:

Conroy Samantha12ORCID,Catto James W.F.12ORCID,Bex Axel34,Brown Janet E.15,Cartledge Jon6,Fielding Alison7,Jones Rob J.8,Khoo Vincent910,Nicol David910,Stewart Grant D.11ORCID,Sullivan Mark1213,Tran Maxine G.B.34ORCID,Woodward Rose1415,Cumberbatch Marcus G.12

Affiliation:

1. Sheffield Teaching Hospitals Foundation Trust Sheffield UK

2. Academic Unit of Urology, Department of Oncology and Metabolism University of Sheffield Medical School Sheffield UK

3. Royal Free NHS Foundation Trust Specialist Centre for Kidney Cancer London UK

4. Division of Surgery and Interventional Science University College London London UK

5. Academic Unit of Clinical Oncology, Department of Oncology and Metabolism University of Sheffield Sheffield UK

6. Leeds Teaching Hospitals NHS Trust Leeds UK

7. Bladder and Renal Cancer Clinical Studies Group National Cancer Research Institute London UK

8. Institute of Cancer Sciences University of Glasgow Glasgow UK

9. Royal Marsden NHS Foundation Trust London UK

10. Institute of Cancer Research London UK

11. Department of Surgery University of Cambridge Cambridge UK

12. Department of Urology Oxford University Hospitals NHS Foundation Trust Oxford UK

13. University of Oxford Oxford UK

14. Action Kidney Cancer Manchester UK

15. International Kidney Cancer Coalition UK

Abstract

ObjectivesTo report the NHS Digital (NHSD) data for patients diagnosed with kidney cancer (KC) in England. We explore the incidence, route to diagnosis (RTD), treatment, and survival patterns from 2013 to 2019.Materials and MethodsData was extracted from the Cancer Data NHSD portal for International Classification of Diseases, 10th edition coded KC; this included Cancer Registry data, Hospital Episode Statistics, and cancer waiting times data.ResultsRegistrations included 66 696 individuals with KC. Incidence of new KC diagnoses increased (8998 in 2013, to 10 232 in 2019), but the age‐standardised rates were stable (18.7–19.4/100 000 population). Almost half of patients (30 340 [45.5%]) were aged 0–70 years and the cohort were most frequently diagnosed with Stage 1–2 KC (n = 26 297 [39.4%]). Most patients were diagnosed through non‐urgent general practitioner referrals (n = 16 814 [30.4%]), followed by 2‐week‐wait (n = 15 472 [28.0%]) and emergency routes (n = 11 796 [21.3%]), with older patients (aged ≥70 years), Stage 4 KCs, and patients with non‐specified renal cell carcinoma being significantly more likely to present through the emergency route (all P < 0.001). Invasive treatment (surgery or ablation), radiotherapy, or systemic anti‐cancer therapy use varied with disease stage, patient factors, and treatment network (Cancer Alliance). Survival outcomes differed by Stage, histological subtype, and social deprivation class (P < 0.001). Age‐standardised mortality rates did not change over the study duration, although immunotherapy usage is likely not captured in this study timeline.ConclusionThe NHSD resource provides useful insight about the incidence, diagnostic pathways, treatment, and survival of patients with KC in England and a useful benchmark for the upcoming commissioned National Kidney Cancer Audit. The RTD data may be limited by incidental diagnoses, which could confound the high proportion of ‘emergency’ diagnoses. Importantly, survival outcomes remained relatively unchanged.

Publisher

Wiley

Subject

Urology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3